Decline in Licensed-Product Sales Due to Contract Expiration
First written in FY2021-Q1. 2 of 4 entries say "Materialised", first in FY2021-Q2. Latest entry: FY2021.
Otsuka Holdings moved to the "Worse" side of this theme in 2022, 1 year before the typical company in this theme (2023).
The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.
7 other companies' latest entry also says "Materialised".
- FY2021MaterialisedAnnual report
「During the consolidated fiscal year, the significant decline in revenue following the expiration of the contracts for Sprycel and Keppra was a factor in」
The decline in revenue following the expiration of the Sprycel and Keppra contracts also occurred for the full fiscal year and was offset by higher revenue from the four global products and the nutraceuticals-related business and other sources. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter, the significant decline in revenue following the expiration of the contracts for Sprycel and Keppra was a factor in」
The decline in revenue following the expiration of the Sprycel and Keppra contracts also occurred in the cumulative third quarter and was offset by higher revenue from the four global products and the nutraceuticals-related business and other sources. - FY2021-Q2MaterialisedAnnual report
「During the cumulative second quarter, the decline in revenue following the expiration of the contracts for Sprycel and Keppra was offset by the four global products Abilify Maintena, Rexulti, JINARC and Lonsurf, and by the nutraceuticals-related business.」
The decline in revenue following the expiration of the Sprycel and Keppra contracts also occurred in the cumulative second quarter and was offset by higher revenue from the four global products and the nutraceuticals-related business. - FY2021-Q1First statedAnnual report
「During the cumulative first quarter, the decline in revenue following the expiration of the contracts for Sprycel and Keppra was offset by the four global products Abilify Maintena, Rexulti, JINARC and Lonsurf, and by the nutraceuticals-related business.」
The decline in revenue following the expiration of the Sprycel and Keppra contracts actually occurred and was offset by higher revenue from the four global products and the nutraceuticals-related business.